Table 1.
Characteristics of NSCLC patients enrolled in the current study.
| Patient Characteristics | Number (%) |
|---|---|
| Total | 112 |
| Age (years) median (range) | 67 (39–84) |
| BMI mean (range) | 26.08 (17.4–44.6) |
| Gender | |
| Male | 86 (76.8) |
| Female | 26 (23.2) |
| Smoking status | |
| Current | 76 (67.9) |
| Former | 21 (18.8) |
| Never | 8 (7.1) |
| NA | 7 (6.3) |
| Pack-years mean (range) | 72.4 (0–200) |
| Histology | |
| Total | 112 |
| Squamous | 45 (40.2) |
| Non-squamous | 53 (47.3) |
| NSCLC | 14 (12.5) |
| Stage | |
| IIIA | 2 (1.8) |
| IIIB | 31 (27.7) |
| IIIC | 5 (4.5) |
| IV | 74 (66.1) |
| Primary location | |
| Left lung | 51 (45.5) |
| Right lung | 57 (50.9) |
| NA | 4 (3.6) |
| Lymph node infiltration | |
| No | 20 (17.9) |
| Yes | 88 (78.6) |
| NA | 4 (3.6) |
| Grade | |
| I | 4 (3.6) |
| II | 19 (17.0) |
| III | 57 (50.9) |
| NA | 32 (28.6) |
| Molecular status | |
| EGFR mutations | 3 (2.7) |
| ALK translocations | 0 (0) |
| PD-L1 status | |
| Positive (>1%) | 27 (24.1) |
| Negative | 9 (8.0) |
| NA | 76 (67.9) |
| PS | |
| 0 | 54 (48.2) |
| 1 | 47 (42) |
| 2 | 8 (7.1) |
| 3 | 3 (2.7) |
| NA | 0 (0) |
| Lines of treatment (LOT) | |
| 1 | 13 (11.6) |
| 2 | 77 (68.8) |
| ≥3 | 22 (19.6) |
| NA | 0 (0) |
| Regimen | |
| Nivolumab | 94 (83.9) |
| Pembrolizumab | 18 (16.1) |
| Best overall response (BOR) | |
| CR | 4 (3.6) |
| PR | 40 (35.7) |
| SD | 26 (23.2) |
| PD | 42 (37.5) |
| NA | 0 (0) |
| Final outcome | |
| PD | 76 (67.9) |
| SD, PR, CR | 19 (17.0) |
| NA | 17 (15.2) |
| Overall survival status | |
| Alive | 52 (46.4) |
| Dead | 60 (53.6) |
Abbreviations: BMI, body mass index; NA, not available; NSCLC, non-small-cell lung cancer; PS, performance status; CR, complete response, PR; partial response; SD, stable disease; PD, progressive disease.